119th Congress · introduced in the Senate · Jun 24, 2026
Modernizing Opioid Treatment Access Act 2.0 of 2026
Official title from Congress.gov
Latest action (Jun 24, 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
30 citations; showing the 25 most recently posted.
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS · lobbying firm or registrant: AMERICAN COLLEGE OF EMERGENCY PHYSICIANS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Alcohol and Drug Abuse
$393,240
Spent on own lobbying
…grams provide at least one formulation of each type of medication for the treatment of opioid use disorder without prior authorization or limitations on dosage S. 4941-Modernizing Opioid Treatment Access Act 2.0, to expand access to methadone through alternative care models using pharmacies
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JOHNS HOPKINS UNIVERSITY · lobbying firm or registrant: JOHNS HOPKINS UNIVERSITY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$340,000
Spent on own lobbying
…and Strengthening Transparency, Accountability, and Integrity Now and for the future of 340B Act, 340B; H.R. 9790, Modernizing Opiod Treatment Access Act 2.0, S.4941, Modernizing Opiod Treatment Access Act 2.0, MOTAA 2.0
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TOBACCO-FREE KIDS ACTION FUND · lobbying firm or registrant: TOBACCO-FREE KIDS ACTION FUND
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$270,000
Spent on own lobbying
…overy (PEER) Support Act H.R. 2586 - Reentry Act H.R. 1510/ S. 1720 - Due Process Continuity of Care Act S. 5425 - Addiction Grants Modernization Act H.R. 9790/S.4941 - Modernizing Opioid Treatment Access Act 2.0 Issues: Medicaid prior authorization requirements Access to addiction treatment services Overdose prevention Raci…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION FOR THE TREATMENT OF OPIOID DEPENDENCE · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Alcohol and Drug Abuse
$20,000
Paid to lobbying firm
Regulation regarding opioids, regulation of fentanyl and methadone access related issues H.R.9790/S.4941, Modernizing Opioid Treatment Access Act, Entirety H.R.5629, To provide that the final rule of the Department of Health and Human Services titled "Medications…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION FOR THE TREATMENT OF OPIOID DEPENDENCE · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
H.R.9790/S.4941, Modernizing Opioid Treatment Access Act, Entirety Monitor the following: H.R.2586, Reentry Act of 2025, Entirety Substance Use Disorder, Medicaid Coverage for…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Alcohol and Drug Abuse
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Insurance
$40,000
Spent on own lobbying
…al Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PINNACLE TREATMENT CENTERS · lobbying firm or registrant: K&L GATES, LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
…atment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. S.4941 - Modernizing Opioid Treatment Access Act 2.0 of 2026.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
…MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$50,000
Spent on own lobbying
…MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Alcohol and Drug Abuse
$50,000
Spent on own lobbying
Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act Issues related to opioids and substance…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS · lobbying firm or registrant: ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Alcohol and Drug Abuse
$54,762
Spent on own lobbying
…ment Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule -Teleprescribing for controlled substances -SUD treatment facility fraud
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES INC.(FKA AMERICAN PSYCHOLOGICAL ASSN · lobbying firm or registrant: AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES INC.(FKA AMERICAN PSYCHOLOGICAL ASSN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$520,000
Spent on own lobbying
…evention in Community Health Centers Act of 2026 H.R.9551, Mental Health Parity Enforcement and Funding Act H.R. 9693, the Patients First Act of 2026 H.R. 9790/S. 4941, Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) H.R. 9990/S. 5120, Increasing Mental Health Options (IMHO) Act H.R.10280, 9-8-8 Implementation Act of…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PINNACLE TREATMENT CENTERS · lobbying firm or registrant: K&L GATES, LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
…atment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. S.4941 - Modernizing Opioid Treatment Access Act 2.0 of 2026.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
…MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$50,000
Spent on own lobbying
…MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASSACHUSETTS MEDICAL SOCIETY · lobbying firm or registrant: MASSACHUSETTS MEDICAL SOCIETY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Alcohol and Drug Abuse
$50,000
Spent on own lobbying
Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act Issues related to opioids and substance…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS · lobbying firm or registrant: ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Alcohol and Drug Abuse
$69,462
Spent on own lobbying
…ment Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION FOR THE TREATMENT OF OPIOID DEPENDENCE · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Alcohol and Drug Abuse
$20,000
Paid to lobbying firm
…epartments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Proposed consolidation of block grants and SAMSHA S.4941, A bill to expand access to methadone through alternative care models using pharmacies, Entirety
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN ASSOCIATION FOR THE TREATMENT OF OPIOID DEPENDENCE · lobbying firm or registrant: VAN SCOYOC ASSOCIATES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$20,000
Paid to lobbying firm
…epartments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Proposed consolidation of block grants and SAMSHA S.4941, A bill to expand access to methadone through alternative care models using pharmacies, Entirety
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF ADDICTION MEDICINE · lobbying firm or registrant: AMERICAN SOCIETY OF ADDICTION MEDICINE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Alcohol and Drug Abuse
$40,000
Spent on own lobbying
…d/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that c…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing